A 70% functional cure rate in treatment-naive patients, reported at EASL 2026, is the number that explains why AusperBio just closed a $120 million Series C, bringing its total raise to $360 million since 2024. That figure reframes what this financing actually is: not a bet on early science, but a commercial runway build for a drug that has already produced Phase 2 signal strong enough to justify a Phase 3 registrational program now underway in China.
The strategic logic is straightforward but the execution challenge is not. Eight FDA-approved drugs already exist for chronic hepatitis B, nearly all nucleos(t)ide analogues and interferons that suppress viral replication effectively but achieve functional cure, defined by the FDA as sustained HBsAg loss below 0.05 IU/mL plus durable HBV DNA suppression, in only a small fraction of patients. An estimated 254 million people worldwide live with chronic hepatitis B, and the overwhelming majority require indefinite suppressive therapy rather than finishing treatment. That structural gap is where AusperBio is positioning AHB-137, its unconjugated antisense oligonucleotide built on the Med-Oligo platform, which suppresses HBsAg production, inhibits viral DNA replication, and is designed to promote immune reactivation rather than simply hold viral load in check.
The $120 million does two things simultaneously. It funds the Phase 3 registrational program for AHB-137 and builds out commercialization infrastructure, meaning regulatory, manufacturing, and launch readiness are being developed in parallel rather than sequentially. That dual spend is a deliberate structural choice: companies that wait for Phase 3 data before standing up commercial capabilities routinely lose 12 to 18 months of potential launch time. The round also accelerates AHB-171, an siRNA candidate using the company’s Au-HALO hepatocyte-targeted delivery platform, explicitly positioned as the second component of a combination backbone strategy for deeper and more durable antiviral responses. RA Capital’s entry as a new investor alongside the existing syndicate of HanKang Capital, Qiming Venture Partners, and CDH Investments signals external validation of that two-asset combination thesis, not just the lead program.
The single marker worth tracking is the FDA’s functional cure endpoint, specifically whether AusperBio pursues a U.S. registrational path for AHB-137 alongside its China Phase 3, or sequences the two. That regulatory geography decision will determine whether the $360 million raised is sized correctly for a regional launch or a global one.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
